bioRxiv · 10.64898/2026.01.30.702627
IDH-mutant inhibitors enhance the sensitivity of IDH1-mutant gliomas to cysteine-methionine deprivation and ferroptosis
Abstract
Cysteine is essential for synthesizing glutathione, the brains main antioxidant, and cysteine deprivation can trigger ferroptosis. Here, using a new mouse model of IDH1-mutant glioma that recapitulates the characteristics of human IDH1-mutant low-grade gliomas, we demonstrate that IDH1-mutant glioma cells are significantly more vulnerable to cysteine deprivation alone or in combination with the ferroptosis inducer RSL3, compared to IDH1-wildtype glioma cells. In addition, treatments with the IDH-mutant inhibitors vorasidenib and ivosidenib further sensitize the cells to ferroptosis. Metabolomics analysis reveals that IDH1-mutant cells have altered cysteine and methionine metabolism with deficiency in transsulfuration, which is further exacerbated by cysteine-methionine deprivation and IDH-mutant inhibitors. Furthermore, dietary cysteine-methionine deprivation alone or in combination with convection-enhanced delivery of RSL3 or ivosidenib in vivo significantly prolongs survival of IDH1-mutant tumor-bearing mice. Our findings suggest that targeting cysteine and methionine metabolism in combination with IDH-mutant inhibition provides promising therapeutic strategies for IDH1-mutant gliomas.
Explore related subjects
Keep this discovery
Explore connections, maps & timelines
Canoll, P., Mela, A., Brand, A., Mahajan, A., Dovas, A., Humala, N., Kanangat, S., Kleinstein, A., Leskinen, S., Nguyen, T., Gao, Q., Upadhyayula, P., Guo, J., Gill, B., Siegelin, M., Sims, P., Stockwell, B., Bruce, J.. 2026-02-02. IDH-mutant inhibitors enhance the sensitivity of IDH1-mutant gliomas to cysteine-methionine deprivation and ferroptosis. https://doi.org/10.64898/2026.01.30.702627
Cite the original work for its findings. Save a collection to share your selection of sources.